Article
The answer may surprise you.
The answer may surprise you.
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
FDA Approves Dupilumab, Marking First Targeted Therapy in a Decade for Chronic Spontaneous Urticaria
2 Commerce Drive
Cranbury, NJ 08512